Compare
UL Solutions Inc. vs Incyte Corp vs Icon PLC vs NeoGenomics Inc
| Latest fiscal year | UL Solutions Inc. ULS | Incyte Corp INCY | Icon PLC ICLR | NeoGenomics Inc NEO |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $3.05B | $5.14B | $8.25B | $727.33M |
| Revenue growth (YoY) | +6.4% | +21.2% | +0.8% | +10.1% |
| Gross margin | 49.5% (computed) | 92.8% (computed) | n/a | 43.2% |
| Operating margin | 17.1% | 29.5% | 5.4% | -15.9% |
| Net margin | 10.6% | 25.0% | 2.8% | -14.9% |
| Net income | $325.00M | $1.29B | $229.34M | -$108.03M |
| EPS (Diluted) | $1.60 | $6.41 | $2.90 | n/a |
| Operating cash flow | $600.00M | $1.41B | $1.04B | $5.23M |
| Free cash flow | $403.00M | n/a | $861.99M | -$21.78M |
| Cash & equivalents | $295.00M | $3.10B | $647.29M | $159.62M |
| Total assets | $2.92B | $6.96B | $16.27B | $1.36B |
| Total liabilities | $1.63B | $1.79B | $7.08B | $523.27M |
| Shareholders' equity | $1.29B | $5.17B | $9.19B | $836.56M |
| Return on year-end equity | 25.1% | 24.9% | 2.5% | -12.9% |
| Shares outstanding | 201.03M | 198.46M | 76.57M | 128.15M |
Revenue, most recent five fiscal years
| Fiscal year | UL Solutions Inc. | Incyte Corp | Icon PLC | NeoGenomics Inc |
|---|---|---|---|---|
| Latest | $3.05B Ended 2025-12-31 | $5.14B Ended 2025-12-31 | $8.25B Ended 2025-12-31 | $727.33M Ended 2025-12-31 |
| 1 year earlier | $2.87B Ended 2024-12-31 | $4.24B Ended 2024-12-31 | $8.19B Ended 2024-12-31 | $660.57M Ended 2024-12-31 |
| 2 years earlier | $2.68B Ended 2023-12-31 | $3.70B Ended 2023-12-31 | $8.05B Ended 2023-12-31 | $591.64M Ended 2023-12-31 |
| 3 years earlier | $2.52B Ended 2022-12-31 | $3.39B Ended 2022-12-31 | $7.74B Ended 2022-12-31 | $509.73M Ended 2022-12-31 |
| 4 years earlier | n/a | $2.99B Ended 2021-12-31 | $5.48B Ended 2021-12-31 | $484.33M Ended 2021-12-31 |